



Recent Therapeutic Advances in Parkinson's Disease

Guest Editor:

Dr. Chieh-Sen Chuang

Department of Neurology,
Changhua Christian Hospital,
Changhua 50006, Taiwan

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

Dear Colleagues,

Parkinson's disease (PD) is a progressive neurological disorder associated with a number of motor, cognitive and psychomotor symptoms. Medication is primarily used as the current treatment to modify neurotransmitters and treat symptoms. The gold standard for PD treatment is dopamine replacement therapy with levodopa. Nevertheless, the treatment for PD is aimed at improving symptoms and cannot slow the progression of the disease. New laboratory medicine research, translation medicinal research, and preclinical studies are providing new directions for treating this disease. The understanding of the mechanism of PD and the development of treatments that influence the fundamental pathology of the condition are advancing.

This Special Issue aims to assemble high-quality original articles and reviews on the current treatments and recent therapeutic developments in PD and related disorders.

Dr. Chieh-Sen Chuang

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)